SAMD4B

SAMD4B is a SAM domain-containing RNA-binding protein that acts as a context-dependent regulator of transcription and Wnt/β-catenin signaling in cancer cells (PMID:20510020, PMID:41154652). Through its SAM domain it suppresses the transcriptional activity of AP-1, p53, and p21 when overexpressed (PMID:20510020). In breast cancer it operates as a pro-tumorigenic factor: SAMD4B stabilizes β-catenin mRNA, raising β-catenin protein levels and upregulating Wnt/β-catenin target genes (Cyclin D1, c-Myc, Axin2) and TCF/LEF activity to drive proliferation, migration, invasion, EMT, and G1-to-S progression, effects abrogated by Wnt inhibition with XAV-939 (PMID:41154652). SAMD4B function is gated by the arginine sensor BAG2, which directly binds SAMD4B; under arginine abundance the BAG2–SAMD4B interaction prevents β-catenin degradation and sustains Wnt activity, whereas arginine deficiency releases SAMD4B, leading to β-catenin degradation, ATF4 stabilization, and enhanced stress survival (PMID:40555234). SAMD4B expression is itself repressed by miR-451 through binding to its 3′-UTR (PMID:34109425).

1. 2010 Medium

   Established the first functional role for SAMD4B as a transcriptional suppressor and localized that activity to its SAM domain, opening the question of which pathways it intersects.

   Evidence Luciferase transcriptional activity assays with overexpression, siRNA knockdown, and deletion mutagenesis in mammalian cells

   PMID:20510020

   Open questions at the time

   • No direct DNA or protein target of the SAM domain identified
   • Mechanism of AP-1/p53/p21 suppression not resolved
   • Single-lab study without independent replication
2. 2021 Medium

   Identified an upstream regulatory input by showing SAMD4B is a direct miR-451 target, linking its expression to a tumor-suppressive miRNA in colorectal cancer.

   Evidence Dual luciferase 3′-UTR reporter assay, miRNA mimic/inhibitor transfection, overexpression rescue, in vitro proliferation/migration assays and xenograft

   PMID:34109425

   Open questions at the time

   • Downstream effectors of SAMD4B in CRC not defined
   • Does not address SAMD4B molecular mechanism, only its abundance
3. 2024 Low

   Proposed a catalytic RNA-modifying role for SAMD4B, mediating 2′-O-methylation that destabilizes APOA2 mRNA and thereby modulating PD-L1 and the tumor immune microenvironment in HCC.

   Evidence 2′-O-methylation assays, multiplex immunofluorescence, single-cell RNA-seq in PDX models

   PMID:38886351

   Open questions at the time

   • Limited methodological detail for the direct SAMD4B–APOA2 mRNA modification
   • Direct catalytic activity not biochemically reconstituted
   • APOA2–PD-L1 interaction not independently validated
4. 2025 Medium

   Defined SAMD4B as a positive regulator of Wnt/β-catenin signaling that stabilizes β-catenin mRNA, connecting its earlier transcriptional effects to a concrete oncogenic pathway in breast cancer.

   Evidence Overexpression/knockdown functional assays, western blot, TCF/LEF reporter, β-catenin mRNA stability analysis, and XAV-939 pharmacological rescue

   PMID:41154652

   Open questions at the time

   • Mechanism by which SAMD4B stabilizes β-catenin mRNA not defined
   • Reconciliation of mRNA stabilization with prior transcriptional suppression role unresolved
   • Single-lab study
5. 2025 High

   Placed SAMD4B downstream of an arginine-sensing checkpoint, showing BAG2 directly binds SAMD4B to couple amino acid availability to Wnt activity versus stress survival.

   Evidence Unbiased screening in cancer cell lines, direct BAG2–SAMD4B and BAG2–arginine binding assays, BAG2 Q167 mutagenesis, and pathway readouts (β-catenin, ATF4, Wnt activity)

   PMID:40555234

   Open questions at the time

   • Structural basis of the BAG2–SAMD4B interface unknown
   • How sequestration of SAMD4B controls β-catenin stability mechanistically unresolved
   • Role of the SAM domain in BAG2 binding not addressed

• It remains unknown how the SAM domain-dependent transcriptional suppression of AP-1/p53/p21 mechanistically integrates with SAMD4B's RNA-binding and β-catenin mRNA-stabilizing activities into a single molecular function.
• No structural model of SAMD4B
• Direct RNA targets beyond β-catenin and APOA2 not catalogued
• Native protein and RNA interactome undefined